Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
As part of large-scale clinical studies prior to market introduction, the AI software has now gone into clinical test with patients, so-called first-in-human applications
Quantib Prostate is an AI-based software solution that advances the MRI prostate reporting workflow and is accessible directly from the radiologist's reading station
The drug will be available in 600 hospitals and 105 DTPs
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
The new hospital is expected to open by March'24
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
The plan is to advance innovative therapies to drug-resistant cancers
The new building is expected to be commissioned by 2024. Post the expansion, Nanavati-Max Hospital will be amongst the largest private sector hospital in western India
Subscribe To Our Newsletter & Stay Updated
